Investigational Drug Details
Drug ID: | D405 |
Drug Name: | Calcipotriol |
Synonyms: | |
Type: | small molecule |
DrugBank ID: | DB02300 |
DrugBank Description: | Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D. |
PubChem ID: | 5288783 |
CasNo: | 112965-21-6 |
Repositioning for NAFLD: | Yes |
SMILES: | O[C@H](\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)C1CC1 |
Structure: |
|
InChiKey: | LWQQLNNNIPYSNX-UROSTWAQSA-N |
Molecular Weight: | 412.6047 |
DrugBank Targets: | Vitamin D3 receptor |
DrugBank MoA: | The precise mechanism of calcipotriol in remitting psoriasis is not well-understood, however, it has been shown to have comparable affinity with calcitriol for the Vitamin D receptor while being less than 1% the activity in regulating calcium metabolism. The Vitamin D receptor (VDR) belongs to the steroid/thyroid receptor superfamily, and is found on the cells of many different tissues including the thyroid, bone, kindney, and T cells of the immune system. T cells are known to play a role in psoriasis and are believed to undergo modulation of gene expression with binding of calcipotriol to the VDR. This modulation is thought to affect gene products related to cell differentiation and proliferation. |
DrugBank Pharmacology: | Calcipotriene is a synthetic analog of vitamin D. In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D3 (cholecalciferol) in the skin. |
DrugBank Indication: | For the treatment of moderate plaque psoriasis in adults. |
Targets: | |
Therapeutic Category: | |
Clinical Trial Progress: | |
Latest Progress: |

Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
---|
Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
---|
Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
---|
Article ID | PMID | Source | Title |
---|